683 Capital Management’s Nuvation Bio NUVB Stock Holding History

683 Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,249,473	Closed	-$1.67M	–	270
2023 Q3	$1.67M	Sell	1,249,473 -325,527	-21%	-$542K	0.13%	88
2023 Q2	$2.83M	Sell	1,575,000 -525,000	-25%	-$893K	0.2%	86
2023 Q1	$3.49M	Sell	2,100,000 -400,000	-16%	-$811K	0.26%	97
2022 Q4	$4.8M	Sell	2,500,000 -80,000	-3%	-$162K	0.41%	62
2022 Q3	$5.78M	Buy	2,580,000 +813,343	+46%	+$2.32M	0.45%	60
2022 Q2	$5.72M	Buy	1,766,657 +486,757	+38%	+$2.12M	0.4%	67
2022 Q1	$6.73M	Buy	1,279,900 +1,033,483	+419%	+$5.81M	0.36%	72
2021 Q4	$2.1M	Hold	246,417	–	–	0.08%	135
2021 Q3	$2.45M	Hold	246,417	–	–	0.1%	107
2021 Q2	$2.29M	Sell	246,417 -353,583	-59%	-$4.03M	0.08%	120
2021 Q1	$6.27M	Sell	600,000 -53,300	-8%	-$596K	0.33%	64
2020 Q4	$7.64M	Buy	653,300 +53,300	+9%	+$554K	0.36%	56
2020 Q3	$6.72M	Buy	+600,000	New	+$6.48M	0.49%	47

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's NUVB Position: Q4 2023 in Review

683 Capital Management sold out of Nuvation Bio (NUVB) in Q4 2023, closing a stake of 1,249,473 shares — an estimated $1.67M sold.

683 Capital Management first reported a position in NUVB in Q3 2020 and held it in 13 quarters. The position peaked at $7.64M in Q4 2020. 116 funds tracked by Wall St. Rank hold NUVB as of Q4 2023.

683 Capital Management reported no remaining Nuvation Bio position as of Q4 2023 after selling out during the quarter.
683 Capital Management sold 1,249,473 Nuvation Bio shares in Q4 2023, an estimated $1.67M.
683 Capital Management first reported a position in Nuvation Bio in Q3 2020 and held it in 13 quarters.
683 Capital Management's Nuvation Bio position peaked at $7.64M in Q4 2020.
116 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2023.

Based on 683 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.